Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586508 · ClinicalTrials.gov registry record · Phase 2
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00586508: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00586508 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 81 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00586508, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
Primary Outcome
Data presented are the percentage of participants without progressive disease (PD) or death from any cause 6 months after registration. PD was a 25% increase in the sum of products of all measurable lesions (or 2 largest lesions if too numerous) over the smallest sum observed (over baseline if no decrease) or clear worsening of any evaluable disease, or appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this
Interventions
- DRUG bevacizumab
- DRUG enzastaurin
- DRUG Enzyme-inducing antiepileptic drugs (EIAED)
- DRUG Non-enzyme inducing antiepileptic drugs (NEIAED)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT00586508 record still lists
NCT00586508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 4 interventions - of which bevacizumab is the first listed.
NCT00586508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00586508 about?
NCT00586508 is a clinical study titled "Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas". The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
What is the current status of trial NCT00586508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2007-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00586508?
The interventions under investigation include: bevacizumab (DRUG), enzastaurin (DRUG), Enzyme-inducing antiepileptic drugs (EIAED) (DRUG), Non-enzyme inducing antiepileptic drugs (NEIAED) (DRUG).
Who is sponsoring clinical trial NCT00586508?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00586508's enrollment target sits among peer trials
81 834th of 2000 higher than 1,159 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia